Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Conexión rápida

Oncology API Products

Oncology API Products

Oncology API Products
Oncology API Products

Dr. Reddys Portfolio of Anti-cancer APIs

We manufacture our Anti-cancer APIs at cGMP API manufacturing facilities which are successfully inspected by international regulatory authorities such as the USFDA, EMEA, ANVISA, PMDA, and Health Canada.

Our team of process experts draws on their integrated understanding of IP, process development (API and formulation), and API manufacturing to ensure that by design, the process is lean, free from potential genotoxic impurities, and scalable to manufacture for early market entries. This is of particular importance to select the optimal synthesis route in the context of the IP situation. Other aspects are the solid-state forms and particle characteristics that are critical in formulation development.

We have incorporated sensitive and rigorous analytical methods to control the impurities at a specified level and extensively studied the flow properties, crystal size/shape, and morphology in accordance with future requirements. In addition, our APIs have been designed to address customized PSD requirements through size reduction and crystallization techniques, resulting in a high probability of successful formulation development.

USPs of our Anti-cancer APIs

  • QbD approach for an efficient process & high-quality output
  • Availability of APIs in various forms.
  • cGMP API manufacturing facility - Successfully inspected by international regulatory authorities.
  • GTIs & impurities are controlled below the TTC limit & ICH limits, respectively.
  • Formulation dossier filed across all major markets.
  • Regulatory filing available across the globe.
  • Completely backward integrated on the Key starting materials to ensure uninterrupted supplies.
  • Adequate capacity to meet the global demands.
  • KSM suppliers with timely deliveries and adherence to stringent specifications.
  • Process safety management guidelines are implemented to enable a sustainable product supply.
  • IP-Compliant API that meets regulatory requirements.

Oncology/Anticancer API Products Manufacturer and Supplier

Dr. Reddy's is a global leader in developing APIs in the Oncology/Anti-cancer therapy area, with deep technical and scientific knowledge established over decades. With a strong presence across six continents and 39 countries, we are a partner of choice for supplying APIs to leading oncology formulators globally.

As one of the largest generic pharmaceutical manufacturers in the world, we have established a niche in generic oncology APIs and partner of choice for supplying APIs to leading oncology formulators globally.

Our various classes of API under anti-cancer portfolio are as follows:

Kinase Inhibitors

Kinase Inhibitors - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

BCL-2 Inhibitor

BCL-2 Inhibitor - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Androgen Receptor (AR) Inhibitors

Androgen Receptor (AR) Inhibitors - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Folate Analog Metabolic Inhibitors

Folate Analog Metabolic Inhibitors - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Nucleoside Metabolic Inhibitors

Nucleoside Metabolic Inhibitors - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Microtubule Inhibitors

Microtubule Inhibitors - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Proteasome Inhibitors

Proteasome Inhibitors - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Thalidomide Analogue

Thalidomide Analogue - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

CYP17 Inhibitor

CYP17 Inhibitor - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Bifunctional Mechlorethamine

Bifunctional Mechlorethamine - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Nucleoside Metabolic Inhibitor

Nucleoside Metabolic Inhibitor - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Alkylating Agent

Alkylating Agent - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Poly (ADP-ribose) Polymerase

Poly (ADP-ribose) Polymerase - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

CXCR4 Chemokine Receptor

CXCR4 Chemokine Receptor - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

GnRH Receptor Antagonist

GnRH Receptor Antagonist - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Chemical Permeation Enhancer

Chemical Permeation Enhancer - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

 

Dr. Reddy, is well-positioned to meet the global demand for Anti-cancer/Oncology APIs. As for many of our APIs. the key starting materials (KW) are backward integrated today. We've also established strategic solid sourcing and logistics partnerships and work closely with our customers to successfully manage Me capacities of our manufacturing units ahead of launches.

To know more about our end-to-end solutions for Anti-cancer/Oncology APIs formulations and Dosage forms. Check out our board portfolio of Anti-cancer/Oncology APIs here (Link) (or) Contact us at api@drreddys.com.

Explore other Therapeutic categories.

Explore

FAQs

  • The oncology API market aims to share and reshape the flow of the pharmaceutical industry's demand.
  • The global oncology API market is expected to exhibit strong growth from 2022 to 2026.
  • The cancer API Market is expected to reach USD 1,48,545.23 Million by 2030 at 7.10% CAGR during the forecast period 2022-2030.

Oncology drugs are therapeutics used to treat cancer, a group of diseases caused by uncontrolled growth and division of abnormal cells. Oncology drugs include a range of different types of medications, such as chemotherapy agents, targeted therapies, immunotherapies, and hormone therapies.

  • Thalidomide Analogues
  • Alkalyting agents
  • Androgen receptors
  • Folate Analog Metabolic
  • Nucleoside
  • Metabolic
  • Microtubule
  • Proteasome Inhibitors

Alkylating agents - cross-linking of DNA strands, inhibiting DNA replication and RNA transcription. Some antimetabolites - Interfere with DNA or RNA synthesis. Alkaloids bind to tubulin and inhibit the formation of microtubules, causing metaphase arrest, and camptothecins inhibit topoisomerase. Others - induces cell death or differentiation.

The knock of the API sector is having a significant effect on the overall cancer API market growth. The Oncology API market has undergone immense changes due to supply chain disruption caused by COVID-19. COVID-19 has disrupted the pharmaceutical industry's production and supply chain.

The global oncology drugs market size was valued at 135.4 Billion in 2020 and is projected to reach 274.4 billion by 2030, registering a CAGR of 7.5% from 2021 to 2030.

Meet with our product experts in one-on-one virtual sessions

Our experts will answer your questions, provide advice, and help you understand our product better

Set Up a Meeting

Renuncia

Ninguna información en este catálogo, incluida cualquier referencia a cualquier producto o servicio, constituye una oferta de venta, ni debe interpretarse como representación de una oferta de venta. Los productos protegidos por patentes válidas no se ofrecen ni se suministran para uso comercial. Sin embargo, las cantidades de investigación de dichos productos pueden ofrecerse con el fin de presentaciones reglamentarias, siempre que existan dichas exenciones reglamentarias. Los compradores deben realizar una evaluación independiente del escenario de la patente para sus respectivos mercados y serán responsables de todas las responsabilidades relacionadas con la patente. Los productos protegidos por patentes válidas en la India no están disponibles para uso comercial, pero estarían disponibles para los fines de la Sección 107A.